Bégaiement et médicaments

Hout, A. Van; Bijleveld, Henny-Annie

doi:10.1016/b978-2-294-74491-4.00010-2

Cited by 1 publication

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A subset of individuals had their exomes sequenced and passed standard quality control. 15 Samples without complete demographic or ICD-10 data were excluded to generate a final study set.…”

Section: Study Populationsmentioning

confidence: 99%

See 1 more Smart Citation

Population-Based Penetrance of Deleterious Clinical Variants

Forrest

Chaudhary

et al. 2022

JAMA

View full text Add to dashboard Cite

IMPORTANCE Population-based assessment of disease risk associated with gene variants informs clinical decisions and risk stratification approaches. OBJECTIVE To evaluate the population-based disease risk of clinical variants in known disease predisposition genes. DESIGN, SETTING, AND PARTICIPANTS This cohort study included 72 434 individuals with 37 780 clinical variants who were enrolled in the BioMe Biobank from 2007 onwards with follow-up until December 2020 and the UK Biobank from 2006 to 2010 with follow-up until June 2020. Participants had linked exome and electronic health record data, were older than 20 years, and were of diverse ancestral backgrounds.EXPOSURES Variants previously reported as pathogenic or predicted to cause a loss of protein function by bioinformatic algorithms (pathogenic/loss-of-function variants). MAIN OUTCOMES AND MEASURESThe primary outcome was the disease risk associated with clinical variants. The risk difference (RD) between the prevalence of disease in individuals with a variant allele (penetrance) vs in individuals with a normal allele was measured. RESULTS Among 72 434 study participants, 43 395 were from the UK Biobank (mean [SD] age, 57 [8.0] years; 24 065 [55%] women; 2948 [7%] non-European) and 29 039 were from the BioMe Biobank (mean [SD] age, 56 [16] years; 17 355 [60%] women; 19 663 [68%]non-European). Of 5360 pathogenic/loss-of-function variants, 4795 (89%) were associated with an RD less than or equal to 0.05. Mean penetrance was 6.9% (95% CI, 6.0%-7.8%) for pathogenic variants and 0.85% (95% CI, 0.76%-0.95%) for benign variants reported in ClinVar (difference, 6.0 [95% CI,] percentage points), with a median of 0% for both groups due to large numbers of nonpenetrant variants. Penetrance of pathogenic/loss-offunction variants for late-onset diseases was modified by age: mean penetrance was 10.3% (95% CI, 9.0%-11.6%) in individuals 70 years or older and 8.5% (95% CI, 7.9%-9.1%) in individuals 20 years or older (difference, 1.8 [95% CI,] percentage points). Penetrance of pathogenic/loss-of-function variants was heterogeneous even in known disease predisposition genes, including BRCA1 (mean [range], 38% [0%-100%]), BRCA2 (mean [range], 38% [0%-100%]), and PALB2 (mean [range], 26% [0%-100%]). CONCLUSIONS AND RELEVANCEIn 2 large biobank cohorts, the estimated penetrance of pathogenic/loss-of-function variants was variable but generally low. Further research of population-based penetrance is needed to refine variant interpretation and clinical evaluation of individuals with these variant alleles.

show abstract

“…A subset of individuals had their exomes sequenced and passed standard quality control. 15 Samples without complete demographic or ICD-10 data were excluded to generate a final study set.…”

Section: Study Populationsmentioning

confidence: 99%

“…release of exome sequence data generated with the functional equivalence pipeline 15 were used (sequence data and quality control described elsewhere 13 ). Variants associated with ClinVar diseases were ascertained from the variant call files using PLINK, version 2.0.…”

Section: Key Pointsmentioning

confidence: 99%

Population-Based Penetrance of Deleterious Clinical Variants

Forrest

Chaudhary

et al. 2022

JAMA

View full text Add to dashboard Cite

show abstract

Bégaiement et médicaments

Cited by 1 publication

References 10 publications

Population-Based Penetrance of Deleterious Clinical Variants

Population-Based Penetrance of Deleterious Clinical Variants

Contact Info

Product

Resources

About